A Rare Case of Imatinib-Induced Pneumonitis

Watson, G. S.

doi:10.19080/ctoij.2016.02.555577

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 10 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the syndrome may resolve with drug discontinuation alone, 9,10 most cases require glucocorticoid therapy for resolution. 11,12 Only a few irreversible cases have been reported. 12,13…”

Section: Discussionmentioning

confidence: 99%

Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia

Kallel

Kassar

Mâaloul

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Pulmonary toxicity causally related to Imatinib (IM) therapy is uncommon in patients with chronic myeloid leukemia. Case report A 61-year-old patient with chronic myeloid leukemia was treated with IM at 400 mg daily dose. One month within IM, he developed skin lesions and then acute dyspnea and non-productive cough. Chest radiograph and high-resolution lung computed tomography (CT) revealed bilateral reticulonodular infiltration in both lungs. According to Naranjo's algorithm, the causality relationship with the drug is probable with a score of 7. The pharmacovigilance investigation was carried out and implicated IM Management & outcome: IM was discontinued and started steroid therapy (Prednisolone®) at 1 mg/kg daily. Two weeks after, the dyspnea, and abnormal X-ray and CT findings are improved. Discussion The early diagnosis of pulmonary toxicity related to IM therapy is needed to avoid further determinal effects of the drug.

show abstract